|
N.A. Chernikova
β-cell dysfunction in type 2 diabetes mellitus: the possibilities of modern antihyperglycemic therapy
|
№12 / 2021
|
|
M.B. Antsiferov (1), O.M. Koteshkova (1), M.S. Novikova (1), N.A. Demidov (2)
Possibilities of dapagliflozin in cardio-reno-metabolic protection in patients with and without type 2 diabetes mellitus
|
№12 / 2021
|
|
N.I. Volkova, S.O. Panenko, A.O. Golubeva
Is non-alcoholic fatty liver disease a consequence of obesity and a predictor of diabetes?
|
№12 / 2021
|
|
A.I. Kochetkov (1), A.P. Pereverzev (1), O.D. Ostroumova (1), D.G. Gusenbekova (1), R.R. Romanovsky (2), N.A. Shatalova (3)
The choice of antianginal therapy for polymordib patients with coronary artery disease and type 2 diabetes mellitus: the benefits of trimetazidine
|
№3 / 2021
|
|
N.A. Chernikova, O.A. Knyshenko, L.P. Ivanova
Ipragliflozin in the treatment of comorbid patients with type 2 diabetes mellitus
|
№4 / 2021
|
|
N.A. Shevkunova (1), M.V. Vorobyov (2), V.V. Gushchin (2)
The use of collagen plates in orthopedic dental rehabilitation of patients with drug-compensated diabetes mellitus
|
№4 / 2021
|
|
M.B. Antsiferov (1), A.V. Zilov (2), O.M. Koteshkova (1), N.A. Demidov (3)
Practical aspects of the use of semaglutide (Ozempic®) in real clinical practice
|
№4 / 2021
|
|
A.S. Ametov (1), E.A. Tertychnaya (2)
Early pathogenetic combined therapy of sugar diabetes type 2: focus on insulin resistance
|
№14 / 2019
|
|
T.N. Markova (1, 2)
Obesity and associated diseases. Modern possibilities of prevention and treatment in real clinical practice
|
№4 / 2019
|
|
E.V. Biryukova, I.V. Solovyova
Do we know everything about the possibilities of metformin in the treatment of type 2 diabetes mellitus? Which of its combinations is the most studied, effective and available for the patient in the real practice of the endocrinologist?
|
№4 / 2019
|
|
L.A. Sharonova, A.F. Verbovoy
The place of glyflozins in the management of type 2 diabetes mellitus
|
№4 / 2019
|
|
A.P. Pereverzev, O.D. Ostroumova, O.N. Tkacheva
Potential drug interactions of oral hypoglycemic drugs that increase the risk of hypoglycemia
|
№4 / 2019
|
Русский
